Get started
Author

Enrico Crea

Observed names: Crea, Enrico, E. Crea
ORCID: 0000-0001-7503-7818
Observed ORCID: 0000-0001-7503-7818
OpenAlex ID: A5050651885
American Journal of Hematology
2006 · ZAJA, Francesco, FANIN, Renato, et al. · American Journal of Hematology · 107
PDF
Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913
2020 · Sabina Chiaretti, Monica Messina, et al. · Haematologica · 89
PDF
Eltrombopag second‐line therapy in adult patients with primary immune thrombocytopenia in an attempt to achieve sustained remission off‐treatment: results of a phase II, multicentre, prospective study
2021 · Elisa Lucchini, Francesca Palandri, et al. · British Journal of Haematology · 61
Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study
2016 · Francesco Zaja, Wilma Barcellini, et al. · American Journal of Hematology · 41
Arsenic Trioxide and All-Trans Retinoic Acid Combination Therapy for the Treatment of High-Risk Acute Promyelocytic Leukemia: Results From the APOLLO Trial
2025 · Uwe Platzbecker, Lionel Adès, et al. · Journal of Clinical Oncology · 34
Neutralizing monoclonal antibodies in haematological patients paucisymptomatic for COVID ‐19: The GIMEMA EMATO ‐0321 study
2022 · Vincenzo Marasco, Alfonso Piciocchi, et al. · British Journal of Haematology · 12
PDF
Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group
2021 · Gian Matteo Rigolin, Francesco Cavazzini, et al. · Hematological Oncology · 11
PDF
Unlocking the potential of synthetic patients for accelerating clinical trials: Results of the first GIMEMA experience on acute myeloid leukemia patients
2024 · Alfonso Piciocchi, Marta Cipriani, et al. · eJHaem · 10
PDF
Single Agent Tagraxofusp in Relapsed/Refractory CD123-Positive Acute Myeloid Leukemia: A Preliminary Analysis of Italian Gimema AML2020 Trial
2023 · Paola Minetto, Sara Rosellini, et al. · Blood · 6
PDF
Safety run-in and part 1 of GIMEMA AML1718: venetoclax combined with FLAI as induction treatment in non–low-risk AML
2025 · Giovanni Marconi, Alfonso Piciocchi, et al. · Blood Advances · 4
Gimema AML1718 Part 1: Planned Interim Analysis of a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia
2022 · Giovanni Marconi, Alfonso Piciocchi, et al. · Blood · 3
Advancing chemogenomic strategies for functional precision medicine in relapsed-refractory T-ALL and ETP-ALL: the GIMEMA ALL2720 trial
2026 · Luca Pagliaro, Roberto Rosati, et al. · npj Precision Oncology · 2
PDF
Regulation 536/2014 and its beneficial impacts on academic clinical research in Italy. Closing the loop
2022 · Alessandra Mancino, Enrico Crea, et al. · Contemporary Clinical Trials Communications · 2
PDF
Preliminary Results of CML1214, a Survey on Ponatinib Compassionate Use in Italy By the Gimema CML Working Party
2019 · Carmen Fava, Matteo Emidio Dragani, et al. · Blood · 2
Pf375 Ibrutinib and Rituximab as Front-line Treatment for Unfit Patients With Chronic Lymphocytic Leukemia (cll). Preliminary Results From the Gimema Llc1114 Study
2019 · F.R. Mauro, S. Molica, et al. · HemaSphere · 2
Centralized MRD Assessment in Gimema AML1718 Trial, a Phase 2 Open-Label Study of Venetoclax Combined with Intensified FLAI Chemotherapy (V-FLAI) As Induction Therapy of Non Low-Risk AML
2024 · Paola Minetto, Fabio Guolo, et al. · Blood
Centralized MRD Assessment at Early Timepoints in Gimema AML1718 Trial, a Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk AML
2023 · Paola Minetto, Fabio Guolo, et al. · Blood
PDF
P553: Preliminary Results of Mrd Analysis of Aml1718, a Phase 2 Open-label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (v-flai) in the Induction Therapy of Non Low-risk Aml
2023 · Paola Minetto, Fabio Guolo, et al. · HemaSphere
P495: Unlocking the Potential of Synthetic Patients for Accelerating Clinical Trials: Results of the First Gimema Experience
2023 · Alfonso Piciocchi, Marta Cipriani, et al. · HemaSphere
ENABLE: treatment combination including decitabine and venetoclax in acute myeloid leukemia secondary to myeloproliferative neoplasms
2023 · Francesco Mannelli, Paola Guglielmelli, et al. · Future Oncology
S244: Effect of Anti-spike Neutralizing Monoclonal Antibodies on Covid-19 Progression and Time to Viral Clearance in Patients With Hematological Malignancies and Sars-cov-2 Infection: the Gimema Experience
2022 · V. Marasco, A. Guidetti, et al. · HemaSphere
AMELIORATE: Early Intensification in FLT3 -Mutated Acute Myeloid Leukemia Based on Peripheral Blast Clearance – MYNERVA-GIMEMA AML1919 Trial
2021 · Francesco Mannelli, Giacomo Gianfaldoni, et al. · Future Oncology
Author response for "EFFICACY OF IDELALISIB AND RITUXIMAB IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA TREATED OUTSIDE OF CLINICAL TRIALS. A REPORT OF THE GIMEMA WORKING GROUP"
2021 · Gian Matteo Rigolin, Francesco Cavazzini, et al. · Publons reviews and discussion
Efficacy of Idelalisib and Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Treated Outside of Clinical Trial. a Report of the Gimema Group
2020 · Gian Matteo Rigolin, Annamaria Frustaci, et al. · Blood
Pf695 Eltrombopag as Second Line Therapy in Adult Patients With Primary Immune Thrombocytopenia (itp) in Attempt to Treatment‐free Remission. Updated Results of a Phase Ii Prospective Study by Gimema Group
2019 · E. Lucchini, F. Palandri, et al. · HemaSphere
Works count: 29
Citation count: 386
H-index: 8
I10-index: 8
Year
Topic
Type